Tirzepatide Obesity Drug Reduces Body Weight by 20 Percent in Eli Lilly Trial

Tirzepatide, a new investigational GLP-1 receptor agonist obesity drug developed by Eli Lilly, has shown promising results in a Phase III clinical trial. Results from the trial show that the injectable drug led to an average body weight reduction of 20 percent, or 50 pounds. Lilly’s drug may give Novo Nordisk’s successful obesity drugs Saxenda and Wegovy some stiff market competition if approved.
Register for our free featured webinar here:
High Multiplex Proteomics Using a Proximity Extension Assay with an Automated Liquid Handling System
xtalks.com/web...
Read more on this story here:
Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial
xtalks.com/tir...
Receive weekly news and webinar updates right in your inbox:
xtalks.com/reg...
Listen live and interact with featured speakers on our upcoming Life Science webinars: bit.ly/2YRzAV0

[@doloreslujan7804]

What are the side affects